coronavirus vaccine in nearly 200 low and middle income countries. The pharma giant has signed a deal with Gavi, the Vaccine Alliance, to provide the doses to the COVAX Facility — a project led by Gavi, the World Health Organization and the Coalition for Epidemic Preparedness Innovations.In August last year, Novavax signed a deal with Pune-based Serum Institute, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low- and middle-income countries and India.
Later, the US drug developer doubled its potential COVID-19 vaccine manufacturing capacity to two billion doses annually.Dubbed NVX‑CoV2373, Novavax's vaccine is currently in mid-stage trials.